Web30 minutes ago · Patient Population: Median age was 63 (range of 31-77); 78% were male; ... 42 pts were evaluable for efficacy, receiving ≥2 treatment cycles (≥8 weeks) with ≥1 post-baseline tumor assessment ... WebMar 31, 2024 · However, efficacy and safety studies on this population are limited. Nebhan et al. 18 reported that median PFS was 6.7 months and OS was 10.9 months in 345 patients aged ≥80 years. In our study, we enrolled 38 patients ≥80 years of age, and PFS and OS in these patients were comparable to those of the patients aged <80 years old.

History of Changes for Study: NCT03512262 - clinicaltrials.gov

WebMar 10, 2024 · A total of 28 patients have enrolled to the trial, 22 of whom were included in the efficacy-evaluable population. Of the 6 remaining patients who were not included in the efficacy analysis, 1... WebDownload Table Response rates for all evaluable patients (efficacy population: n ¼ 37 patients) from publication: Replacement of bortezomib with carfilzomib for multiple … pinja saikkonen

Safety and efficacy of GEMOX plus donafenib and tislelizumab as …

WebApr 11, 2024 · The efficacy analyses were performed in evaluable analysis population, which consisted of patients who received at least one dose of study drugs and had best overall response assessment. ... COVID-19, some patients could not return to the site for follow-up in time, resulting in that only eight patients were evaluable for efficacy. … WebA. Muyle, G. Marais, in Encyclopedia of Evolutionary Biology, 2016 Effects on Effective Population Size. With pure selfing, the effective population size, N e, is decreased by … WebJun 2, 2024 · Results: The efficacy-evaluable cohort comprised 150 adults (vs 121 previously) with 17 different solid tumor types. Median age was 58.5 years; 91% of pts had ECOG PS 0–1 and 37% had received ≥2 prior lines of therapy. Median survival follow-up was 30.6 months. ORR was 61.3% (n = 92/150; 95% CI: 53.1–69.2), including 25 … pinjarra museum